News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Nagi El Saghir

Articles by Nagi El Saghir

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

ByNagi El Saghir,Yoon Sim Yap,Yesim Eralp,Seock-Ah Im,Hamdy Abdel Azim,Julie Rihani,Nikita Volkov,Shin-Cheh Chen,Hakan Harputluoglu,Patrapim Sunpaweravong,Yuan-Ching Chang,Teresa Delgar Alfaro,Jiwen Wu,Huilin Hu,Melissa Gao,Yen-Shen Lu

August 15th 2024

16 Primary Results From the Randomized Phase II RIGHT Choice Trial of Premenopausal Patients With Aggressive HR+/HER2− Advanced Breast Cancer Treated With Ribociclib + Endocrine Therapy vs Physician’s Choice Combination Chemotherapy

ByMelissa Gao,Yen-Shen Lu,Eznal Izwadi Bin Mohd Mahidin,Hamdy Abdel Azim,Yesim Eralp,Yoon Sim Yap,Seock-Ah Im,Julie Rihani,James Bowles,Teresa Delgar Alfaro,Jiwen Wu,Khemaies Slimane,Nagi El Saghir

April 28th 2023

Latest Updated Articles

Trending on CancerNetwork

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era

Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population

ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC

Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC

© 2025 MJH Life Sciences^®

All rights reserved.